TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis C$15.29 +0.29 (+1.93%) As of 09/23/2026 10:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnership About Fennec Pharmaceuticals Stock (TSE:FRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$15.29▼C$15.2950-Day RangeC$13.85▼C$17.6352-Week RangeC$7.59▼C$17.64Volume140 shsAverage Volume1,206 shsMarket CapitalizationC$536.17 millionP/E RatioN/ADividend Yield2.02%Price TargetN/AConsensus RatingStrong Buy Company Overview Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Read More Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FRX Stock News HeadlinesFennec Pharmaceuticals (TSE:FRX) Insider Sells C$206,160.00 in StockSeptember 9, 2026 | insidertrades.comRobert Christopher Andrade Sells 106,844 Shares of Fennec Pharmaceuticals (TSE:FRX) StockAugust 29, 2026 | insidertrades.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings BeatAugust 11, 2026 | finance.yahoo.comFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | markets.businessinsider.comFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 22, 2026 | financialpost.comFFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 15, 2026 | financialpost.comFFennec Shareholders Approve Governance, Compensation and Equity PlansJune 10, 2026 | tipranks.comSee More Headlines FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed this year? Fennec Pharmaceuticals' stock was trading at C$10.60 on January 1st, 2026. Since then, FRX shares have increased by 44.2% and is now trading at C$15.29. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 13.34% and a negative net margin of 6.21%. Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' top institutional shareholders include Cornerstone Capital Inc. (0.30%). Insiders that own company stock include Rostislav Christov Raykov, Southpoint Capital Advisors Lp, Robert Christopher Andrade, Chris Anigeron Rallis, Pierre Sayad, Adrian J Haigh, Khalid Islam and Jeffrey Hackman. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS). Company Calendar Last Earnings11/07/2024Today9/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:FRX CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.12) Trailing P/E RatioN/A Forward P/E Ratio25.32 P/E GrowthN/ANet Income-C$800.44 thousand Net Margins-6.21% Pretax MarginN/A Return on Equity-13.34% Return on Assets8.88% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio10.17 Sales & Book Value Annual SalesC$59.22 million Price / Sales9.05 Cash FlowC$1.31 per share Price / Cash Flow11.66 Book ValueC$1.23 per share Price / Book12.45Miscellaneous Outstanding Shares35,067,000Free FloatN/AMarket CapC$536.17 million OptionableNot Optionable Beta3.72 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (TSE:FRX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FRX Stock Alerts